Browsing Tag
Takeda Pharmaceutical Company Limited
5 posts
Zasocitinib meets all endpoints in Phase 3 trials, Takeda (NYSE: TAK) eyes FDA submission in 2026
Takeda’s once-daily TYK2 pill hits PASI 100 in Phase 3 psoriasis trials. Find out what this means for rivals, regulators, and Takeda’s pipeline strategy.
December 19, 2025
How recombinant therapies are reshaping bleeding disorder treatment for children in 2025
Recombinant therapies are replacing plasma-derived treatments for pediatric bleeding disorders—see what’s driving this shift in 2025 and who’s leading.
September 10, 2025
Vonvendi gets green light for pediatric bleeding disorder care in FDA expansion
Find out how the FDA's expanded approval of Vonvendi opens new treatment avenues for children and adults with all types of von Willebrand disease.
September 7, 2025
Quebec lists Takeda’s FRUZAQLA for metastatic colorectal cancer under RAMQ formulary
Quebec approves public reimbursement of Takeda’s FRUZAQLA for metastatic colorectal cancer, expanding treatment access in Canada.
August 28, 2025
Lupin partners with Takeda to launch novel gastrointestinal drug Vonoprazan in India
In a significant development, Lupin Limited, a global pharmaceutical leader, announced a non-exclusive patent licence agreement with Takeda…
September 19, 2024